High-dose chemotherapy and CD34+ cell reinfusion in breast cancer
Author Information
Author(s): C Chabannon, K Cornetta, J-P LoW, C Rosenfeld, M Shlomchik, S Yanovitch, J-P Marolleau, G Sledge, G Novakovitch, EF Srour, B Burtness, J Camerio, G Gravis, J Lee-Fischer, C Faucher, I Chabbert, D Krause, D Maraninchi, B Mills, L Kunkel, F Oldham, D Blaise, P Viens
Hypothesis
Can selected CD34+ peripheral blood cells support haematopoietic recovery after high-dose chemotherapy in patients with poor-prognosis breast cancer?
Conclusion
Selected CD34+ cells safely support haematopoietic recovery following high-dose chemotherapy in patients with poor-prognosis breast cancer.
Supporting Evidence
- Patients were randomized into two groups to compare the effects of selected and unselected CD34+ cells.
- Haematopoietic recovery occurred at similar times in both groups.
- No side effects related to the infusion of selected cells were observed.
- The frequency of epithelial tumor cells in aphereses was low.
- Patients received high-dose chemotherapy according to institutional protocols.
Takeaway
Doctors tested if special blood cells could help patients recover faster after strong cancer treatment, and they found that these cells worked just as well as regular ones.
Methodology
Patients were randomized to receive either unmanipulated mobilized blood cells or selected CD34+ cells after high-dose chemotherapy.
Limitations
The study had a small sample size and was limited to patients with poor-prognosis breast cancer.
Participant Demographics
Patients had histologically documented adenocarcinoma of the breast, considered high-risk due to metastatic disease or more than eight positive nodes.
Statistical Information
P-Value
0.0024
Statistical Significance
p=0.0024
Want to read the original?
Access the complete publication on the publisher's website